KRAS and colorectal carcinoma: In some cases, this is unequivocally useful; for example, in CRC, the choice of first-line therapy depends on the presence or absence of specific mutations in KRAS that confer resistance to the EGFR-targeted monoclonal antibody cetuximab8.